share_log

BRIEF-Syndax Announces Orphan Drug Designation Granted To Axatilimab

BRIEF-Syndax Announces Orphan Drug Designation Granted To Axatilimab

Brief-Syndax宣佈授予Axatilimab孤兒藥物稱號
路透社 ·  2021/03/31 19:49

March 31 (Reuters) - Syndax Pharmaceuticals Inc :
   * SYNDAX ANNOUNCES ORPHAN DRUG DESIGNATION GRANTED TO AXATILIMAB FOR TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE

Source text for Eikon:  Further company coverage:

((Reuters.Briefs@thomsonreuters.com;)

路透3月31日電-Syndax PharmPharmticals Inc：*Syndax宣佈授予AXATILIMAB孤兒藥物稱號，用於治療慢性移植物抗宿主疾病Eikon的源文本：進一步的公司報道：(Reurs.Briefs@thomsonreurs.com；)

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論